Peter Schmid
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- Cancer Research top 0.2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 135
- Cancer Immunotherapy and Biomarkers 66
- Cancer Treatment and Pharmacology 54
- HER2/EGFR in Cancer Research 50
-
- Advanced Breast Cancer Therapies 101
- Prostate Cancer Treatment and Research 12
- Lung Cancer Treatments and Mutations 11
- Co-authors
- Sherene Loi (54 shared papers)Hope S. Rugo (39 shared papers)Hiroji Iwata (28 shared papers)Eric P. Winer (25 shared papers)Carlos H. Barrios (26 shared papers)Sylvia Adams (23 shared papers)Leisha A. Emens (19 shared papers)Luciana Molinero (16 shared papers)
- Journals
- Journal of Clinical Oncology (45 papers)Cancer Research (44 papers)Annals of Oncology (41 papers)ESMO Open (6 papers)Future Oncology (5 papers)
- Partner nations
- United KingdomUnited StatesSpain
In The Last Decade
Peter Schmid
197 papers receiving 11.3k citations
Peter Schmid's Hit Papers
Peers
Comparison fields: 5 of 113
- Oncology 7.1k
- Cancer Research 2.6k
- Immunology 2.2k
- Pulmonary and Respiratory Medicine 2.7k
- Molecular Biology 1.9k
Countries citing papers authored by Peter Schmid
This map shows the geographic impact of Peter Schmid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Schmid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Schmid more than expected).
Fields of papers citing papers by Peter Schmid
This network shows the impact of papers produced by Peter Schmid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Schmid. The network helps show where Peter Schmid may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Schmid, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 208 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 3084 |
| 2 | Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2019 | 877 |
| 3 | Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer Hit paper breakdown → | 2022 | 654 |
| 4 | Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 583 |
| 5 | Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study Hit paper breakdown → | 2018 | 482 |
| 6 | Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 357 |
| 7 | Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 351 |
| 8 | 2016 | 223 | |
| 9 | Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study Hit paper breakdown → | 2021 | 214 |
| 10 | 2021 | 207 | |
| 11 | 2020 | 138 | |
| 12 | 2017 | 138 | |
| 13 | 2019 | 137 | |
| 14 | 2017 | 135 | |
| 15 | 2018 | 115 | |
| 16 | 2022 | 110 | |
| 17 | 2009 | 109 | |
| 18 | 2015 | 109 | |
| 19 | 2021 | 100 | |
| 20 | 2019 | 97 |
About Peter Schmid
Peter Schmid is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 208 papers that have together received 11.5k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (101 papers), Cancer Immunotherapy and Biomarkers (66 papers), Cancer Treatment and Pharmacology (54 papers), HER2/EGFR in Cancer Research (50 papers), Breast Cancer Treatment Studies (28 papers), Cancer Genomics and Diagnostics (18 papers), Prostate Cancer Treatment and Research (12 papers) and Lung Cancer Treatments and Mutations (11 papers). The work is most often cited by research in Oncology (7.1k citations), Cancer Research (2.6k citations), Immunology (2.2k citations), Pulmonary and Respiratory Medicine (2.7k citations) and Molecular Biology (1.9k citations). Peter Schmid has collaborated with scholars based in United Kingdom, United States and Spain. Frequent co-authors include Sherene Loi, Hope S. Rugo, Hiroji Iwata, Eric P. Winer, Carlos H. Barrios, Sylvia Adams, Leisha A. Emens, Luciana Molinero, Véronique Dièras and Jane Yuet Ching Hui. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, ESMO Open and Future Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.